On the other hand, favorable-risk karyotype AML patients, e.g., Core Binding Factor (CBF) AML patients and normal-karyotype FLT3-wild-type (wtFLT3) NPM1-mutated (mNPM1) patients, are usually not considered candidates for allo-HSCT in first complete remission (CR1). The gene discussed is NPM1; the disease is acute myeloid leukemia.